MedImmune FluMist complete response
This article was originally published in Pharmaceutical Approvals Monthly
MedImmune submits FluMist "complete response" Aug. 26 to FDA's second action letter for the nasal flu vaccine, dated July 10 (Pharmaceutical Approvals Monthly, August 2002, In Brief). Wyeth has begun producing 4 mil. doses of FluMist in hopes of launching for the 2002 flu season; the doses will not be valid for the 2003 flu season. MedImmune says a 2002 launch would be "tight," as approval would be needed by Sept.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.